Meet MAR002 from Marea Therapeutics: a new approach moving to clinical trials
From the desk of Jorge D. Faccinetti, PWN cofounder and publisher – For many patients, pegvisomant is a lifesaver. I’m a perfect example. At first, nothing worked to bring my IGF-1 down. We cycled through other medications (the usual insurance nonsense), but Dr. Blevins was confident pegvisomant would do the trick. And almost like magic, my IGF-1 came into range, and I’ve been in control since 2010. By every measure, pegvisomant, marketed by Pfizer as Somavert, has been a total success for me. But it still comes with real burdens: daily injections, which are expensive, and the ongoing grind of managing it all. If you are living with acromegaly, the list of treatment options has grown over the years. Still, most of these developments have focused on new formulations of somatostatin analogs like octreotide.
By way of background, Octreotide works at the source. It’s a somatostatin analog, which mimics the body’s natural “off switch” for growth hormone. It works on the tumor cells, so they release less GH. Less GH means less IGF-1. In some instances, it can also shrink the tumor. Think of it as turning down the tap. It’s typically a long-acting injection and oral option. It only works well if the tumor has the right receptors to bind to.
Pegvisomant, on the other hand, works at the destination. It doesn’t touch the tumor and doesn’t lower growth hormone at all. Instead, it blocks the GH receptor in the body (mainly on the liver), so even though the hormone is floating around, it can’t deliver its message. The liver stops making IGF-1. Think of it as unplugging the receiver rather than turning down the tap. Because it blocks the final step, it’s very effective at normalizing IGF-1, even in people who didn’t respond to octreotide, like me.
Now, a San Francisco biotechnology company called Marea Therapeutics is testing a new formulation called MAR002 that uses the same strategy as pegvisomant.
More about MAR002?
MAR002 is an experimental, engineered human antibody that blocks the growth hormone receptor that growth hormone needs to attach to send its message. When GH can’t deliver that signal, IGF-1 levels come down. As we mentioned, this is the same basic strategy used by this therapy, a medication some patients already know. What makes MAR002 different is how it’s built. Unlike the discontinued Astra Zeneca drug, Marea’s MAR002 is more than a formulation improvement, it is engineered to stay active in the body longer. That change opens the door to much less frequent dosing.
What the early research showed
Marea has completed its first Phase 1. As is standard, it was done in healthy adult volunteers, and its main job was to check safety and to see whether the drug lowers IGF-1 the way it’s designed to. Marea reported that in this early study, MAR002 was well tolerated, with no serious adverse events. Importantly, it produced lasting drops in IGF-1, with reductions of up to 64% at its peak. The company noted that this level of suppression appears greater than what’s been reported for existing acromegaly therapies, and it behaved in a way that could support dosing as infrequently as once every two weeks. These are encouraging early signals with evidence that the drug does what it was designed to do. They are not yet proof that it controls acromegaly in patients. That’s the question the next stage of testing is built to answer.
Why less-frequent dosing matters
For patients who need a receptor-blocking medicine, today’s option (pegvisomant) typically means a daily injection. Managing a daily shot, year after year, can be taxing. MAR002’s potential to be given as little as every two weeks could ease that burden considerably. Less frequent dosing isn’t just about convenience; over time it can make treatment easier to stick with, which matters when the goal is steady, long-term disease control. It’s one of the main reasons this drug has drawn attention in the acromegaly community.
The latest
MAR002 shared Phase 1 findings in an oral presentation at ENDO 2026, the Endocrine Society’s annual meeting, in Chicago. Marea has since moved the program into a larger Phase 2 study in people with acromegaly. The trial is open and enrolling. If you’re interested in whether a MAR002 study might be an option for you, the best next steps are to talk with your doctor and to search for the trial on ClinicalTrials.gov, where you can find eligibility details and study locations.
The bottom line
MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
We’ll follow MAR002’s progress closely and keep the community updated as the patient trial moves forward. Use the QR Codes above or click on the this link for more information and trial details.
Stay tuned for a very informational podcasts with Dr. Ethan Weiss, Marea’s Chief Scientific Officer and principal investigator and PWN contributor Dr. Kevin Yuen coming soon.
© 2026, J D Faccinetti. All rights reserved.